收购详情 - 布里斯托尔-迈尔斯斯奎布公司成功完成对Mirati Therapeutics, Inc.的收购[1] - 收购使Mirati成为布里斯托尔-迈尔斯斯奎布公司的全资子公司[1] - 收购使布里斯托尔-迈尔斯斯奎布公司的非GAAP每股收益在2024年预计每股将减少约0.35美元[3] 顾问团队 - Evercore Inc.和摩根士丹利公司担任布里斯托尔-迈尔斯斯奎布公司的财务顾问，Kirkland & Ellis LLP担任法律顾问[4] - Centerview Partners LLC担任Mirati的财务顾问，Skadden, Arps, Slate, Meagher & Flom LLP担任法律顾问[4] 公司介绍 - 布里斯托尔-迈尔斯斯奎布公司是一家全球生物制药公司，致力于发现、开发和提供帮助患者战胜严重疾病的创新药物[5]

Parradee Kietsirikul Introduction Last year, we saw an uptick in M&A from big pharma to combat the significant drug patent cliff later in the decade. Amongst the worst anticipated patents cliffs is Bristol Myers Squibb (NYSE:BMY) who announced a number of deals into the end of 2023. Last year former COO and now current CEO Chris Boerner revised the $10bn-13bn sales target for new drugs by 2025 to $10bn by 2026, raising concerns over the company ability to completely offset patent loss in later years. Op ...

股价表现 - Bristol Myers Squibb (BMY) 最新收盘价为 $49.57，较前一交易日下跌了 1.08% [1] - 过去一个月，这家生物制药公司的股价下跌了 4.17%，表现不佳 [2] 财务预测 - Bristol Myers Squibb 即将发布财报，预计每股收益为 $1.69，同比下降 7.14%，营收预计为 $11.13 亿美元，同比下降 2.41% [3] 估值分析 - 估值方面，Bristol Myers Squibb 的 Forward P/E 比率为 6.93，低于行业平均值 22.43 [7] - BMY 目前的 PEG 比率为 1.39，略高于行业平均值 1.8 [8] 行业排名 - Medical - Biomedical and Genetics 行业的 Zacks Industry Rank 为 96，在所有 250+ 个行业中排名前 39% [9] - Zacks Industry Rank 是根据行业内个股的平均 Zacks Rank 计算的，研究表明排名前 50% 的行业表现比排名后 50% 的行业好一倍 [10] 提示 - 请继续关注 Zacks.com，以了解这些影响股价的指标和更多信息 [11]

临床试验结果 - Opdivo (nivolumab)与Yervoy (ipilimumab)在第3阶段CheckMate -214试验中持续展示出长期生存结果[1] - Opdivo plus Yervoy在中等和不良风险患者中维持了8年的疗效[1] - Opdivo plus Yervoy在所有随机患者中展示了长期益处[1] - CheckMate -214的更新数据显示Opdivo plus Yervoy在晚期或转移性肾细胞癌患者中提供了最长的生存益处[3] 安全性信息 - Opdivo plus Yervoy的安全性可控，没有出现新的安全信号[2] - 重要安全信息：免疫介导的严重和致命不良反应[37] - 免疫介导的不良反应可能在任何器官系统或组织中发生，早期识别和管理至关重要[38] - OPDIVO和YERVOY可能导致免疫介导的肺炎、结肠炎、肝炎、内分泌疾病、甲状腺疾病、糖尿病等不良反应[41][43][45][48][50][53][56] - 免疫介导的肾炎和肾功能障碍是可能的[57] - OPDIVO和YERVOY可能引起免疫介导的皮肤反应，包括皮疹或皮炎[58][59] - 其他临床上显著的免疫介导的不良反应包括心血管、神经系统、眼部、消化系统、肌肉骨骼和结缔组织、内分泌系统等[62] - OPDIVO和YERVOY可能引起严重的输液相关反应[63] - 接受OPDIVO或YERVOY治疗的患者在进行异基因造血干细胞移植前或后可能出现致命和其他严重并发症[64] - 在治疗过程中密切关注移植相关并发症的迹象，并及时干预[65] - OPDIVO和YERVOY可能在孕妇身上造成胚胎-胎儿毒性[66] - 在多发性骨髓瘤患者中，将OPDIVO与沙利度胺类似物和地塞米松联合使用会增加死亡风险[67] - 由于潜在的严重不良反应，建议妇女在接受治疗期间和最后一次剂量后至少5个月内不要母乳喂养[68] - 在临床试验中，接受OPDIVO治疗的患者出现严重不良反应的比例较高，包括肠绞痛、低钠血症、谷草转氨酶升高和脂肪酶升高等[69] - 在多个临床试验中，接受OPDIVO和YERVOY联合治疗的患者出现严重不良反应的比例较高，包括腹泻、结肠炎和发热等[70] - OPDIVO在临床试验中最常见的不良反应包括疲劳、皮疹、肌肉骨骼疼痛、恶心、发热、瘙痒等[71],[72] 合作与商业化 - Bristol Myers Squibb感谢参与CheckMate -214临床试验的患者和研究人员[5] - OPDIVO和YERVOY可能引起免疫介导的皮肤反应，包括皮疹或皮炎[58][59] - OPDIVO与YERVOY联合治疗在多种癌症类型中进行临床试验，包括未治疗的晚期非小细胞肺癌、胃癌、结直肠癌等[74] - Bristol Myers Squibb与Ono Pharmaceutical合作开发和商业化OPDIVO，扩大了在全球范围内的权利[76]

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Results continued to show superior progression-free survival (PFS) and objective response rates (ORR) in patients treated with Opdivo plus ...

BALA CYNWYD, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Karuna Therapeutics, Inc. (Nasdaq – KRTX) Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash tran ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of chemotherapy (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The dual immunotherapy combination of Opdivo and Yervoy d ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tu ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $50, moving -0.62% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.37%. Elsewhere, the Dow saw a downswing of 0.62%, while the tech-heavy Nasdaq depreciated by 0.19%.The biopharmaceutical company's shares have seen a decrease of 2.01% over the last month, not keeping up with the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56%.The investment community will be paying close attent ...

BlackJack3D Yet another cheap Big Pharma stock Having recently written about the cratered pharma stock and value opportunity in Pfizer (PFE), charting the big pharma sell-offs, reveals a nearly as strong downtrend in Bristol-Myers Squibb (NYSE:BMY). The company is in a similar phase of R&D cycling and acquisitions to fill its next cycle of drugs for the next decade. Bristol Myers does not have the stigma around it from being a vaccine producer during COVID-19, but they also have their issues to reckon w ...